Evotec to acquire Gates Foundation-backed Just Biotherapeutics

Biotech-CRO hybrid Evotec is continuing its deals, buys and collabs strategy with its acquisition of U.S. biologics company Just Biotherapeutics.

The German company is spending a small sum, just $90 million, on its latest purchase, but boosts its offering in biologics oncology, central nervous system disorders, pain, inflammation, metabolics and infectious diseases.